Author: acn

HONG KONG, March 4, 2026 - (ACN Newswire via SeaPRwire.com) – The 42nd Hong Kong International Jewellery Show, organised by the Hong Kong Trade Development Council (HKTDC), opens today at the Hong Kong Convention and Exhibition Centre (HKCEC) and runs for five consecutive days until 8 March. It is held concurrently with the 12th Hong Kong International Diamond, Gem & Pearl Show which opened on Monday (2 March) at AsiaWorld-Expo and concludes on 6 March. The two shows bring together some 4,000 exhibitors from over 40 countries and regions, forming the world’s largest one-stop jewellery marketplace.Jenny Koo, Deputy Executive Director of the HKTDC, said: “Alongside the expanded Hall of Fame, the show will feature the debut of the Hard Pure Gold Pavilion and the Hong Kong Watch Manufacturers Association Pavilion. Furthermore, Uzbekistan is participating for the first time with a delegation of 10 companies, showcasing a wide range of gold jewellery. Through diversified exhibit profiles, we aim to create more collaboration opportunities for the industry and reinforce Hong Kong’s status as a global jewellery trading hub.”Kent Wong, Chairman of the Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem & Pearl Show Fair Organising Committee, said: “Hong Kong is an international trade and sourcing centre and our twin jewellery shows play a pivotal role. Continuing the successful ‘Two Shows, Two Venues’ format, the fairs attract global jewellery professionals for sourcing and networking, helping the industry capture the latest global market trends.”International brands converge, key zones expandAt the Hong Kong International Jewellery Show, the Hall of Fame has expanded by over 40%, welcoming more renowned international jewellery brands. Among them, Turkish exhibitor Hosgor Kuyumculuk Mucevherat Ticaret Limited Sirketi (Booth: CEC 3B-D15) presents a 35.5-carat diamond necklace that combines exquisite craftsmanship with brilliant radiance. Another highlight is the Hall of Extraordinary, which features exhibitors such as Hong Kong’s Glamour Fine Jewelry Enterprise Company (Booth: CEC GH-C16), showcasing a bracelet featuring Colombian emeralds paired with diamonds and rubies in a radiant and luxurious style.New pavilions highlight oriental aestheticsWith hard pure gold technologies gaining popularity in the Chinese Mainland, the Hard Pure Gold Pavilion (Booth: CEC 3E-F02) features 11 exhibitors organised by the World Gold Council. The pavilion showcases innovative techniques that produce harder, lighter and brighter gold pieces capable of setting a variety of gemstones. Also, the Hong Kong Watch Manufacturers Association Pavilion highlights crossover craftsmanship between jewellery setting and watchmaking.The fairs also feature several events celebrating oriental aesthetics. Today, the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited presented the awards for the Hong Kong International Fashion Chuk Kam Jewellery Design Competition. The competition encourages designers to create culturally rich and commercially viable gold jewellery for the ASEAN and the Middle East markets. Tomorrow (5 March) will see the awards presentation of the inaugural International Fei Cui Jewellery Design Competition, organised by the Hong Kong Jade Association, honouring designers who skilfully blend jadeite with global cultural elements.Antique treasures and cutting-edge designAntique jewellery remains highly sought-after by collectors and high-end customers for its historical value and craftsmanship. The Antique & Vintage Jewellery Galleria presents an array of rare pieces, including a bi-colour enamel diamond piece from World Coins Co., Ltd. (Booth: CEC CH-N12), with a history spanning over a century. Design pieces are equally captivating, the Designer Galleria welcomes 10 Korean designers this year. Together with the Young Jewellery Designer Arena, participated by the Asia Pacific Creator Association and the Asia Jewelry Culture Design and Crafts Association, about 50 designer exhibitors will showcase their diverse creativities in the fairground.The HKTDC continues to nurture local talents in the jewellery industry. In partnership with the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, Hong Kong Jewellery & Jade Manufacturers Association, Hong Kong Jewelry Manufacturers’ Association, and Diamond Federation of Hong Kong, the 27th Hong Kong Jewellery Design Competition returns under the theme “Pure Elegance – Natural Beauty”, offering a stage for local professional designers and students. The awards ceremony will be held tomorrow (5 March) at the HKCEC, with winning pieces on display to demonstrate innovative design.E-commerce and technology empower industry growthTo help exhibitors expand into the Chinese Mainland market and develop their online sales channels, the fairs continue the collaboration with Taobao Tmall. For the first time, the fairs also welcome Douyin, partnering with influencers and KOLs for on-site live streaming to promote exhibitors’ products. On 7 March, a seminar will feature experts discussing the latest online marketing trends and tactics.Another seminar on 5 March will explore how AI and new technologies enhance competitiveness, optimise production, and drive product innovation in the jewellery industry.Engaging events to connect and inspireA diverse lineup of events will be held to foster industry dialogue. These include a seminar by Dr Jack Ogden, a distinguished British historian and jewellery authority, who will analyse the evolution of jewellery craftsmanship and changing aesthetic tastes throughout history. The jewellery parades will highlight themes such as intangible cultural heritage jewellery, curated selections from the Antique & Vintage Jewellery Galleria, as well as highlights from the Hall of Extraordinary, Designer Galleria, and gold jewellery.Full list of the winning entries from Hong Kong International Fashion Chuk Kam Jewellery Design Competition: https://bit.ly/46B5edLPhoto download: https://bit.ly/46GadtLThe 42nd Hong Kong International Jewellery Show opens today at the HKCEC, alongside the 12th Hong Kong International Diamond, Gem & Pearl Show at AWE, together gathering around 4,000 exhibitors from over 40 countries and regionsAnthony Lam, Chairman of the Federation of Hong Kong Industries (front row, centre); Bernard Chan, Under Secretary for Commerce and Economic Development (front row, fifth right); Sophia Chong, Executive Director of the HKTDC (front row, fifth left); Kent Wong, Chairman of the HKTDC twin jewellery shows’ Fair Organising Committee (front row, fourth right); Winston Chow, Chairman of the HKTDC Jewellery Advisory Committee (front row, fourth left), and other officiating guests attended today’s networking receptionThe Hall of Fame has expanded by over 40% this year, featuring more international brandsThe World Gold Council debuts the Hard Pure Gold Pavilion, featuring 11 exhibitors to showcase innovative hard pure gold craftsmanship to international buyersThe Hong Kong Watch Manufacturers Association Pavilion makes its first appearance, exhibiting luxury timepieces that integrate jewellery setting craftsmanshipShenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02) presents 24K gold necklaces themed around oriental palatial and modern Chinese styles, employing six traditional gold techniquesHong Kong exhibitor Present Watch & Jewelry (Booth: CEC 1CON-019) showcases a diamond wristwatch inspired by the Northern Song masterpiece “Ode to the Lotus”, with a dial crafted to evoke a lotus pondTurkish brand Zen Diamond (Booth: CEC 3B-C12), which appointed global celebrity Jennifer Lopez as its ambassador in 2025, presents a series of diamond pieces at the showHong Kong designer Austy Lee (Booth: CEC 1EF32) launches a zebra-inspired-bangle for the Year of the HorseWinners of the Hong Kong International Fashion Chuk Kam Jewellery Design Competition pictured at the award ceremony with distinguished guestsFair detailsHong Kong International Jewellery ShowDateOpening hours4 March (Wednesday)10:30am to 6:30pm5-7 March (Thursday to Saturday)10am to 6:30pm8 March (Friday)10am to 5:30pmVenueHong Kong Convention and Exhibition Centre, 1 Expo Drive, Wan ChaiPress registration and Media CentreMedia representatives can register at the entrance of HKCEC Hall 1D Concourse, or at the HKTDC Media Centre (G/F, Expo Drive Entrance, HKCEC) by presenting a business card or media identification.* Hong Kong International Diamond, Gem & Pearl ShowDateOpening hours2 March (Monday)10:30am to 6:30pm3-5 March (Tuesday to Thursday)10am to 6:30pm6 March (Friday)10am to 5:30pmVenueAsiaWorld-Expo, Hong Kong International Airport, Lantau, Hong KongPress registration and Media CentreMedia representatives can register at the entrance of AsiaWorld-Expo’s East Lobby (Next to Hall 5) or at the Media Centre (Room 201C, 2/F) by presenting a business card or media identification.** For security reasons, all media will be required to present a name card and identity card (or passport) for press registration. Individuals with a valid press pass will be required to present their identity card (or passport) again at the entrance to the exhibition halls for identity verification. Please allow sufficient time for registration and admission.Websites Hong Kong International Jewellery ShowHong Kong International Diamond, Gem & Pearl ShowWebsitehttp://hkjewelleryshow.hktdc.comhttp://hkdgp.hktdc.comActivity listhttps://www.hktdc.com/event/hkjewellery/en/intelligence-hubhttps://www.hktdc.com/event/hkdgp/en/intelligence-hubShuttle bus arrangementshttps://www.hktdc.com/event/hkjewellery/en/travel-to-fairground-hkcechttps://www.hktdc.com/event/hkdgp/en/travel-to-fairground-aweHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) - Core Concepts Physio, one of Singapore's leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain.Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved.To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked.A Smarter, More Complete Way to Diagnose Heel PainPhysiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support.The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in:More accurate, holistic diagnosesFully optimised treatment strategiesFewer flare-ups and recurrencesClearer, consistent guidance for patientsFaster and more sustainable outcomes"Many patients struggle because plantar fasciitis isn't caused by just one issue," said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. "It's a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms."A Case Study Demonstrating Collaborative SuccessIn a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts.A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient's daily load decreased significantly — allowing physiotherapy progress to continue without setbacks.Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running."This case reflects what we see frequently," said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. "Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery."Making Multidisciplinary Care Accessible NationwideThrough this collaboration, patients with plantar fasciitis now benefit from:Joint physiotherapy–podiatry assessmentsAligned clinical decision-makingConsistent communication across providersA thorough evaluation of both the cause and consequence of heel painA fully optimised recovery pathway"Our multidisciplinary team brings together the best of both professions," said Mr Chng Chye Tuan. "Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands."About Core Concepts PhysiotherapyCore Concepts Physio is one of Singapore's largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580.About Podiatry QuestPodiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care.Contact DetailsOrganization: Core Concepts Pte LtdContact: Clemence LimWebsite: https://www.coreconceptsphysio.sg Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

东京, 2026年3月5日 - (亚太商讯 via SeaPRwire.com) - 专注于工业用贵金属展开业务的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（总公司：东京都中央区、执行总裁：田中 浩一朗）宣布在烧结金(Au)接合技术“AuRoFUSE™ Preforms”中，确立了金凸块※1的转印技术。通过本技术，在具有复杂结构的半导体芯片及衬底※2上也能形成AuRoFUSE™Preforms（以下简称“金凸块”）。制成的金凸块转印基板转印后的金凸块通过实现金凸块转印所带来的优势本技术是通过制作预先形成金凸块的基板（以下简称“转印基板”），实现向对象半导体芯片及衬底进行凸块转印的方法。在用作转印基板的硅基板上开孔，并于其开孔部位形成金凸块。通过形成金凸块使其完全填满开孔部位，可将其固定在基板上，而无需担心在处理过程中金凸块会脱落。另一方面，转印时通过加热使金凸块收缩，从而在开孔部位与金凸块间形成微小间隙。因此，只需施加垂直方向的力，即可轻松拔出。以往的金凸块形成制程是采用直接在对象半导体芯片及衬底上形成凸块的方法，对于具有凹凸结构、贯通孔等复杂形状的工件，由于存在光刻胶的高度不稳定等课题，导致难以应对。本次转印技术通过另行制作金凸块，可实现仅在目标位置转印金凸块，因此也能适用于复杂形状。此外，该技术还能应对由于担心剥离液等造成的损伤而难以通过光刻※3制程的半导体芯片及衬底。转印基板的制作及转印/接合制程(1) 作为转印基板，准备硅基板(2) 在硅基板上涂布光刻胶(3) 曝光显影为目标图案(4) 在硅基板上通过蚀刻进行开孔(5) 使用刮板等工具嵌入AuRoFUSE™(6) 在常温下真空干燥AuRoFUSE™，并刮取光刻胶上多余的金浆料(7) 剥离光刻胶后即可形成转印基板(8) 将想要形成金凸块的对象（半导体芯片及衬底）对准转印基板，进行10MPa、150℃、1分钟的热压。随后垂直抬升基板，即可完成金凸块的转印(9) 将转印后的基板经过20MPa、200℃、10秒的热压后进行接合以往的金凸块形成制程关于烧结金接合技术“AuRoFUSE™ Preforms” TANAKA开发的“AuRoFUSE™ Preforms”是通过将由金微粒子与有机溶剂构成的浆料，预先形成凸块形状的接合技术。在200℃、20MPa、10秒的热压后，虽然在压缩方向上显示出约10％的收缩率，但在水平方向上较少变形，并具有足以承受实际应用的接合强度※4。而且，由于以化学稳定性较优异的金为主要成分，封装后兼具较高的可靠性。本技术是一种能够实现半导体配线微细化和多种芯片集成（较高密度化）的技术，预计不仅能应用于LED（发光二极管）和LD（半导体激光器）等光学器件，还能广泛应用于个人电脑和智能手机等数字设备，以及为满足车载零部件、MEMS等近年来日益增长的半导体小型化与较高性能化需求做出贡献。关于凸块形成技术，以往有焊料凸块和镀层凸块两种主要方法。但是，焊料凸块随着焊点间距不断变得微细，焊料在熔化时会横向扩展，因此存在电极之间接触引起短路的风险。此外，镀层凸块虽然可实现窄间距，但由于接合时需要相对较高的压力，因此存在造成半导体芯片损坏的问题。本技术正是为解决这些课题而开发的，旨在应用于下一代高密度封装和光电融合器件。关于“AuRoFUSE™”及TANAKA所从事的金材料 “AuRoFUSE™”是在粒径控制至次微米大小的金粒子中混合了有机溶剂的浆料接合材料。与金的熔点（约1064℃）相比，其特点是能在约200℃的低温下进行接合。金是一种具有较低电阻和较高热传导率的材料，因此在处理较大电流的功率半导体和较大发热量的更高密度芯片中，能够实现高效散热并减少能量损耗。此外，作为贵金属中抗氧化性、稳定性特别强的材料，在封装后不易发生腐蚀或离子迁移（金属迁移导致短路的现象），长期使用仍能保持较高的可靠性。TANAKA凭借自创业以来，凭借所积累的贵金属素材开发技术优势，在半导体领域不断致力于以发挥重要作用的金为代表的贵金属材料开发。此外，还拥有从原料的采购到材料开发、制造、回收的一站式业务体系，有效利用有限的贵金属资源，同时为发展半导体技术和实现可持续社会做出贡献。（※1） 凸块：突起的电极（※2） 衬底：用于搭载半导体芯片并提供电气与机械支撑的基板（※3） 光刻：在基板上形成微细电路图案的技术（※4） 接合强度：指抗剪强度(横向载荷测试中的强度)关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此开展广泛业务活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: http://www.acnnewswire.com/docs/files/20260305_CH.pdf Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Tashkent, Uzbekistan, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) -�FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium � a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework.Why Uzbekistan - Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter.Asterium's project is designed to operate fully within this framework.What Was Deployed - FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium's business model. The core deployment covers three key layers:Banking infrastructure � management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems.Digital asset infrastructure � crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan's Mirasmanda ledger for HUMO asset support.Compliance and exchange � a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off.The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards � all within a regulated environment.How the Partnership Works - FinHarbor operates as Asterium's strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion."This project required deep architectural customization � from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards," said Ilya Podoynitsyn, CEO of FinHarbor. "The core phase is complete, and we are already scaling the platform with new products and business use cases."��What's Next - With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform's functionality to support additional business lines built on the deployed stack.About FinHarborFinHarbor provides modular technology infrastructure for launching compliant financial products � from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets.Social LinksLinkedIn: https://www.linkedin.com/company/finharbor/Blog: https://www.finharbor.com/blog�Media contactBrand: FinHarborContact: Media teamWebsite: https://www.finharbor.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CLEVELAND, Ohio, Mar 4, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, LLC ("Formerra"), a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials, today announced the appointment of Tom Kelly as Chief Executive Officer ("CEO"). A seasoned executive with over 30 years of specialty and engineered materials experience, Tom is known for leading teams to drive differentiated growth and building high-performing organizations set up for long-term success. The former CEO, Cathy Dodd, will stay on as Special Advisor to the Board and will remain an investor in the Company.Tom brings extensive commercial, supply chain, and distribution experience with a strong background in scaling global enterprises in the engineered materials sector. After previous roles at Cabot Microelectronics and Chemtura, Tom's most recent role was Senior Vice President of Engineered Materials at Celanese, where he led key commercial and operational initiatives across engineered polymers and specialty segments. He brings a strong blend of leadership, industry insight, and supply-chain expertise to his new role as CEO of Formerra."Formerra has built a tremendous reputation as a technical selling organization and for putting customers first, supported by exceptional people and supplier partners in the engineered materials ecosystem," said Tom Kelly. "I'm excited about the opportunity to build on its strengths and accelerate capabilities in new geographies and adjacent materials. We will continue investing in our people, distribution network, and in our product line card to strengthen Formerra's competitive position globally."About FormerraFormerra, headquartered in Cleveland, Ohio, is a leading distributor of engineered thermoplastic resins, additives, elastomers, and other specialty materials. Formerra supports leading blue-chip customers and suppliers with its extensive specialty materials portfolio and value-added combination of commercial and technical expertise, global market knowledge, and industry-leading logistics and service capabilities. Formerra offers highly specialized technical, processing, design and regulatory support for critical end market applications in the healthcare, consumer, industrial and mobility markets. Formerra operates an asset-light network of 37 warehouses and 21 bulk transfer stations located in North America, Central America, Europe, and Asia.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

美国俄亥俄州克利夫兰, 2026年3月4日 - (亚太商讯 via SeaPRwire.com) - 领先的工程热塑性树脂、添加剂、弹性体及其他特种材料分销商 Formerra, LLC（“Formerra”）今日宣布任命 Tom Kelly 为公司首席执行官（CEO）。Tom 是一位资深高管，在特种材料和工程材料领域拥有超过30年的经验，以带领团队推动差异化增长并打造具备长期成功基础的高绩效组织而闻名。公司前任首席执行官 Cathy Dodd 将继续担任董事会特别顾问，并将继续作为公司的投资者。Tom 在工程材料领域拥有丰富的商业、供应链和分销经验，并在推动工程材料行业全球企业规模化发展方面具备深厚背景。在曾任职于 Cabot Microelectronics 和 Chemtura 之后，Tom 最近担任 Celanese 工程材料部门高级副总裁，负责领导工程聚合物和特种材料领域的关键商业及运营举措。在担任 Formerra 首席执行官的新角色中，他将凭借卓越的领导能力、深厚的行业洞察以及供应链专业经验，推动公司持续发展。Tom Kelly 表示：“Formerra 作为一家技术型销售组织，并始终坚持以客户为中心，在工程材料生态体系中与优秀的员工和供应商伙伴共同建立了卓越的声誉。我很高兴有机会在这一坚实基础上继续发展，并在新的地域市场和相关材料领域加速拓展能力。我们将继续投资于人才、分销网络以及产品组合，以进一步增强 Formerra 在全球市场的竞争地位。”关于 FormerraFormerra 总部位于美国俄亥俄州克利夫兰，是一家领先的工程热塑性树脂、添加剂、弹性体及其他特种材料分销商。凭借其丰富的特种材料产品组合，以及商业与技术专长、全球市场洞察以及行业领先的物流与服务能力的增值整合，Formerra 为众多知名蓝筹客户和供应商提供支持。Formerra 还为医疗保健、消费品、工业及出行等关键终端市场应用提供高度专业化的技术、加工、设计及法规合规支持。目前，Formerra 在北美、中美洲、欧洲和亚洲运营着一个轻资产网络，包括 37 个仓库和 21 个散装中转站。媒体联络Jackie Morris Marketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144来源: Formerra Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月4日 - (亚太商讯 via SeaPRwire.com) - 由香港贸易发展局（香港贸发局）主办的第42届香港国际珠宝展，今日起一连五日（3月4至8日）在湾仔香港会议展览中心举行，而第12届香港国际钻石、宝石及珍珠展已率先于周一（3月2日）在亚洲国际博览馆揭幕，展期至3月6日。两展云集逾40个国家及地区、约4,000家展商，组成全球最大一站式珠宝商贸平台。香港贸发局副总裁古静敏表示：「今年香港国际珠宝展的品牌精粹廊规模进一步扩大，更首设硬足金展馆及香港表厂商会展馆。乌兹别克亦首次组团参展，带来10家企业展示黄金珠宝产品。我们期望透过多元化的展会内容，为业界开拓更多合作机会，进一步巩固香港作为国际珠宝贸易枢纽的地位。」香港国际珠宝展及香港国际钻石、宝石及珍珠展筹备委员会主席黄绍基表示：「香港作为国际商贸及採购中心，香港贸发局珠宝双展发挥着举足轻重的作用。今年延续『两展两地』的成功模式，吸引世界各地珠宝业人士前来参观採购，相信有助业界拓展国际商机，并掌握环球市场最新动向。」国际品牌云集 焦点展区阵容升级香港国际珠宝展备受瞩目之一的品牌精粹廊(Hall of Fame)展区规模较往年扩大逾四成，其中的土耳其展商 Hosgor Kuyumculuk Mucevherat Ticaret Limited Sirketi（展位：会展 3B-D15）于展会带来35.5卡钻石颈錬，工艺与光芒兼备。另一焦点展区珠宝精粹廊(Hall of Extraordinary)同样精彩，香港展商骏邑国际(Glamour Fine Jewelry Enterprise Company)（展位：会展 GH-C16）带来以哥伦比亚祖母绿配衬钻石及红宝石的手鍊，呈现华丽气派。首设展馆展示东方美学内地近年兴起硬足金技术，世界黄金协会组织11家企业于硬足金展馆展出（展位：会展 3E-F02），向国际展示硬足金崭新工艺，相比传统足金饰品更硬、更轻、更亮，能够镶嵌不同宝石物料，迎合时尚珠宝潮流。此外，香港表厂商会展馆亦会重点展示珠宝与腕表的跨界工艺。展会期间举行多场关于东方美学珠宝的活动，包括今日举行的香港国际时尚足金首饰设计比赛颁奖典礼，比赛以「黄金新思路‧新丝路的文化交融与创新」为主题，鼓励设计师创作出迎合东盟及中东市场，兼具文化内涵和商业潜力的金饰作品。明天（3月5日）将举行国际翡翠玉器首饰设计大赛颁奖典礼，表扬将翡翠玉石与国际文化结合的优秀设计人才。古董珍藏与设计新锐古典首饰向来深受收藏家及高端客群青睐，其歷史价值与经典工艺亦令作品别具收藏价值。古典精粹廊（Antique & Vintage Jewellery Galleria）展出多件古董珍品，包括展商World Coins Co., Ltd.（展位：会展CH‑N12）带来的一套拥有超过100年歷史的双色珐琅钻石首饰。别具匠心的设计同样极具吸引力，珠宝设计精选展区（Designer Galleria）今年特别邀请十位韩国设计师参与，连同新晋珠宝设计师专区（Young Jewellery Designer Arena）、亚太区创作师协会以及亚洲珠宝文化设计工艺协会，合共汇聚约50家设计师展商，展示多元创意。香港贸发局一向致力培育香港珠宝设计人才，并积极推动珠宝业的创意发展，今年再次与香港珠宝首饰业商会、香港珠宝玉石厂商会、香港珠宝制造业厂商会及香港钻石总会携手举办第27届香港珠宝设计比赛，以「未琢之韵．自然之美」为题，让本地专业珠宝设计师及学生一展才华。颁奖典礼将于明天（3月5日）于会展举行，获奬作品展示创新的珠宝设计。电商与科技助力行业发展为协助展商开拓中国内地市场及线上销售渠道，今年展会继续与电商平台淘宝天猫合作，同时抖音亦会首次参与，联同网红达人在现场为参展商进行产品直播。大会将于3月7日举办研讨会，由业界专家及网红剖析最新线上营销趋势及技巧。此外，针对创新科技对珠宝行业的影响，3月5日举办的研讨会将探讨人工智能及新技术如何协助业界提升竞争力、优化生产效率及推动产品创新。精彩活动促进业界交流展会期间将安排多场专题活动，包括由英国歷史学家及珠宝权威Dr. Jack Ogden主讲的研讨会，深入分析珠宝工艺的演变。多场珠宝汇演将展示不同主题系列，包括非物质文化遗产珠宝、古典精粹廊精选、珠宝精粹廊精选、设计师精选，以及黄金首饰。香港国际时尚足金设计比赛完整得奖名单：https://bit.ly/46B5edL图片下载：https://bit.ly/46GadtL由香港贸易发展局主办的第42届香港国际珠宝展今日于湾仔会展隆重开幕，连同于亚博馆举行的第12届香港国际钻石、宝石及珍珠展，共汇聚来自全球超过40个国家及地区，约4,000家参展商。香港工业总会主席林世豪（前排正中）、香港特别行政区政府商务及经济发展局副局长陈百里（前排右五）、香港贸发局总裁张淑芬（前排左五）、香港国际珠宝展及香港国际钻石、宝石及珍珠展筹备委员会主席黄绍基（前排右四）、香港贸发局珠宝业谘询委员会主席周允成（前排左四）及一众嘉宾，出席今日（3月4日）举行的第42届香港国际珠宝展及第12届香港国际钻石、宝石及珍珠展交流酒会。今年「品牌精粹廊」展区规模较去年扩大逾四成，汇聚更多国际知名珠宝品牌。世界黄金协会于珠宝展首设硬足金展馆，合共11家展商，向国际展示硬足金崭新工艺。香港表厂商会展馆首度登场，展出多款结合珠宝镶嵌工艺的奢华腕錶系列。中国内地展商赛菲尔珠宝（展位：会展 3E-E02）带来主打「东方宫廷」与「新中式」风格，运用六种古法黄金工艺制作的24K黄金项链。香港展商比辰钟錶珠宝（展位：会展 1CON-019）带来一款以北宋名作《爱莲说》为设计灵感的钻石手表，将表面打造成莲花池一样。土耳其展商Zen Diamond（展位：会展 3B-C12）于2025年邀请国际名人Jennifer Lopez担任全球代言人，今次为珠宝展带来一系列的钻石作品。香港设计师Austy Lee（展位：会展 1E - F32）趁马年推出以斑马为灵感的手镯，别出心裁。「香港国际时尚足金设计比赛」一众得奖者与嘉宾合照。展会资料：香港国际珠宝展展览日期开放时间3月4日（星期三）上午10时30分至下午6时30分3月5至7日（星期四至六）上午10时至下午6时30分3月8日（星期日）上午10时至下午5时30分展览地点湾仔博览道1号香港会议展览中心记者登记处及新闻中心新闻界代表请携同名片及记者证到香港会议展览中心展览厅1D大堂，或到香港贸发局新闻中心（香港会议展览中心博览道入口──新翼地下）即场办理记者入场证** 香港国际钻石、宝石及珍珠展展览日期开放时间3月2日(星期一)上午10时30分至下午6时30分3月3至5日 (星期二至四)上午10时至下午6时30分3月6日 (星期五)上午10时至下午5时30分展览地点香港大屿山香港国际机场亚洲国际博览馆记者登记处及新闻中心新闻界代表请携同名片及记者证到亚洲国际博览馆东大堂入口 （5号展馆门口旁），或到新闻中心（2楼201B会议室）即场办理记者入场证****基于保安理由，记者须出示工作证及身份证或护照登记，方能办理记者证，持大会发出记者证入场前，保安人员亦会要求出示身份证明文件，以确认身份。请预留足够时间办理记者证及入场。相关网页 香港国际珠宝展香港国际钻石、宝石及珍珠展展览网页http://hkjewelleryshow.hktdc.com/schttp://hkdgp.hktdc.com/sc两展穿梭巴士安排https://www.hktdc.com/event/hkjewellery/sc/travel-to-fairground-hkcechttps://www.hktdc.com/event/hkdgp/sc/travel-to-fairground-awe展会活动https://www.hktdc.com/event/hkjewellery/sc/intelligence-hubhttps://www.hktdc.com/event/hkdgp/sc/intelligence-hub香港贸发局新闻中心：http://mediaroom.hktdc.com/sc传媒查询香港贸易发展局传讯及公共事务部：简惠宜电话：(852) 2584 4055电邮：winnie.wy.kan@hktdc.org黄家欣电话：(852) 2584 4524电邮：katy.ky.wong@hktdc.org张敏萱电话：(852) 2584 4137电邮：jane.mh.cheung@hktdc.org香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

LONDON, Mar 4, 2026 - (ACN Newswire via SeaPRwire.com) - BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure.BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets.Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture.In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling.“Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.”BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants.With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026.About Base58 LabsBase58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/Media ContactBase58 Labs PR TeamEmail: info@base58labs.comBASIS Official Website: https://basis.pro/Base58 Labs Official Website: https://base58labs.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BANGKOK, Mar 4, 2026 - (ACN Newswire via SeaPRwire.com) - Thailand has launched a new phase in its national research and innovation strategy with the introduction of the Thailand RISE Fund, a rebranded national research funding initiative aimed at accelerating the transition from academic research to real-world economic and social impact.The initiative was highlighted at the Thailand RISE Fund Forum: RISE UP THAILAND, hosted in collaboration with Chulalongkorn University. The national forum brought together policymakers, researchers, industry leaders, and innovation stakeholders to explore how Thailand can strengthen its position in the global innovation economy.From Research Output to Real-World ImpactThailand’s research performance has expanded significantly over the past decade, but national leaders say the country’s next challenge is ensuring that research delivers tangible benefits.Professor Dr. Wilert Puriwat, President of Chulalongkorn University, emphasized the importance of translating knowledge into national progress. “A country advances not simply because it produces knowledge, but because it can transform knowledge into a coordinated system that connects policy, research, innovation, and industry,” he said.He added that universities must play a strategic role in national development. “Our goal is to move research beyond the laboratory and into real-world applications that deliver measurable economic and social benefits while strengthening Thailand’s long-term competitiveness.”Building a National Innovation SystemNational research leaders stressed that Thailand’s science and innovation system must operate with clearer direction and stronger coordination.Professor Dr. Sompong Klaynongsruang, President of Thailand Science Research and Innovation (TSRI), said collaboration across sectors is essential. “The development of Thailand’s science, research and innovation system must be driven systematically—from strategic policy and targeted funding to the practical use of research outcomes in the economy and society.”She noted that cooperation among universities, government agencies, and the private sector will be key to achieving long-term impact. “When all sectors move forward together, research will not only generate knowledge but also create meaningful national transformation.”More Than a RebrandingThe transition to the Thailand RISE Fund represents a strategic shift in how Thailand supports research and innovation.Asst. Professor Dr. Ake Pattaratanakun, Chairman of Thailand RISE Fund Strategic Communications Subcommittee, said the initiative reflects a new national priority. “Thailand has significantly increased its research output over the past decade, but the key challenge today is not quantity. It is how research creates economic and social value.”He explained that the Thailand RISE Fund is designed to bridge the gap between research and industry. “Thailand RISE Fund is intended to serve as a systemic intermediary, linking research to real economic needs and focusing on proof of impact rather than publication numbers.”Four Pillars of the RISE FrameworkThe Thailand RISE Fund operates under a strategic framework built on four pillars:ResearchInnovationScience ExcellenceEcosystemThe ecosystem pillar emphasizes partnerships among universities, businesses, government agencies, and communities to support a comprehensive innovation economy.Expanding Opportunities NationwideThe Thailand RISE Fund is also expanding engagement across Thailand to ensure broader participation in the innovation system. Regional forums and outreach activities are designed to help researchers and entrepreneurs develop collaborative projects aligned with local economic strengths. This approach reflects a shift from centralized funding toward a more inclusive and distributed innovation ecosystem.Research for National DevelopmentThe Thailand RISE Fund aims to transform the role of research in Thailand’s development strategy. “Our vision is to move Thai research from ‘research for journals’ to ‘research for the nation,’” Dr. Ake said.By focusing on measurable impact and long-term value creation, the initiative seeks to strengthen Thailand’s competitiveness while supporting sustainable economic and social development.For more information, please contact pr@tsri.or.th#ThailandRiseFund Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月4日 - (亚太商讯 via SeaPRwire.com) - 随着智能驾驶从辅助功能向端到端大模型演进，高保真仿真与数据闭环已成为行业发展的核心引擎。弗若斯特沙利文最新发布的《2026年中国物理AI仿真及数据平台研究报告》揭示了这一关键基础设施领域的惊人现状：市场正呈现出极度的头部集中效应，而五一视界（51Sim）以53.5%的市场份额，确立了其在中国端到端高阶智驾仿真及数据平台市场的绝对霸主地位。数据显示，2025年中国该领域前五大厂商占据了超过90%的市场份额，其中51Sim一家独大，其体量超过了其余所有主要竞争对手（智行众维、康谋、深信科创、沛岱）的总和。这种“一超多强”的格局，深刻反映了物理AI仿真行业的高壁垒特性。正如报告所指，该行业不仅要求供应商具备极高的图形学与动力学建模技术，更需拥有深厚的汽车行业Know-how以及海量的长尾场景数据积累。51Sim之所以能占据半壁江山，正是得益于其在智能驾驶领域多年的深耕，成功构建了从虚拟场景重构、合成数据生成到数据回流闭环的一体化能力，精准击中了车企在L2+及以上高阶智驾研发中的痛点。这一市场格局也预示着物理AI技术的强大迁移潜力。智能驾驶作为物理AI最早规模化的落地场景，其成熟的仿真体系正在向具身智能机器人等领域溢出。51Sim在智驾领域建立的标准化环境与数据资产，为其跨行业扩展奠定了坚实基础。未来，随着中国物理AI仿真市场在2030年有望突破1800亿元规模，51Sim凭借其在智驾赛道的压倒性优势，极有可能成为推动具身智能、航空航天等多领域智能化转型的通用底座。综上所述，51Sim的领跑不仅是商业上的成功，更是中国物理AI基础设施成熟度的标志。在算法日益趋同的今天，拥有高质量仿真数据平台的厂商，将掌握定义下一代智能系统的关键话语权。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – MMG Limited (“MMG”, stock code: 1208) has today announced its 2025 Annual Results, delivering record revenue and profit. The exceptional result reflects disciplined operational and financial management, supported by favourable commodity prices.Watch the Message from CEO:https://drive.google.com/file/d/17KFqXpd_2sjdZDKfBBMBv1ee09Zic-e6/view'usp=drive_linkSafety is MMG’s first value and the Company recorded a Total Recordable Injury Frequency (TRIF) of 2.06 per million hours worked for the full year 2025. The Significant Events with Energy Exchange Frequency (SEEEF) was 0.80 per million hours worked, up slightly from 0.78 per million hours worked in 2024.Total earnings reached record highs. EBITDA rose to US$3,412.1 million, while EBIT increased to US$1,999.1 million. MMG also generated record net operating cash flow of US$2,689.5 million and free cash flow of US$1,608.1 million. Net profit after tax increased to US$955.2 million (US$509.4 million attributable to equity holders), up from US$366.0 million (US$161.9 million attributable to equity holders) in 2024.“We ended the year strongly, delivering an excellent finish in terms of our operational and financial performance,” said MMG’s CEO Ivo Zhao. “This included Las Bambas achieving their second-highest annual copper production, up 27 per cent from 2024, with records set for annual ore mined, ore milled and overall recovery rates.”MMG’s balance sheet is now substantially stronger, with reduced net debt and a gearing ratio at a record low of 33 per cent. This included the Las Bambas joint venture (JV) dividend payment, which facilitated the early repayment of US$500 million in Khoemacau borrowings. The remaining funds were used to repay other debts, deleverage the company’s balance sheet and support the early stages of Khoemacau's expansion.MMG’s total copper production rose 27 per cent year-on-year to 506,899 tonnes, driven by technology, innovation and stable operation across both pits at Las Bambas. Las Bambas contributed US$4,447.0 million in revenue (49 per cent year-on-year growth), contributing the largest share of the Group’s revenue growth. Total zinc production increased by six per cent to 232,060 tonnes, underpinned by a record year at Dugald River. Precious metals production at Rosebery also performed well.“While we remain mindful of the dynamic market environment, we are focused on delivering our growth plans and harnessing emerging technologies to drive long-term value for shareholders,” said Mr Zhao. “An important contribution to MMG’s growth pipeline is our Khoemacau Expansion project. Our plan is to increase annual production capacity to 130,000 tonnes of copper in copper concentrate by 2028, with the potential for 200,000 tonnes over time.”During 2025, the Company’s market capitalization exceeded HK$100 billion, including strong demand for its first convertible bond.MMG’s 2025 Annual Results Report is available here.Las BambasKhoemacauDugald RiverRoseberyKinseverePhoto download link: https://drive.google.com/drive/folders/1o9ArIgbJSAT2z1UCt8ttB69L9l9jiebx'usp=drive_linkAbout MMGFounded in 2009, MMG’s vision is to create a leading international mining company for a low carbon future. The company is headquartered in Melbourne, Australia and Hong Kong and Beijing, China and listed on the Hong Kong Stock Exchange (HKEX1208).MMG’s portfolio supports copper, zinc and cobalt production, with soon to be nickel – products that are critical to achieving global decarbonisation and electrification targets. With operations in Australia, Botswana, the Democratic Republic of Congo and Latin America, the company makes a direct contribution to the economic and social development of its host countries.In 2025, MMG released its first nature strategy and progressed a refresh of its climate strategy. MMG's membership of the UN Global Compact further aligns the company with global leaders on human rights, climate action, and governance. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ANTWERPEN, BELGIUM, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) - OMP, a leading provider of AI-powered supply chain planning solutions, launches Unison Decision-Centric Planning, a new approach that helps organizations move from reactive, process-driven planning to proactive, event-driven decision-making.Built on OMP's flagship Unison Planning™ platform, Unison Decision-Centric Planning combines advanced AI, autonomous agents, real-time scenario modeling, and human validation to accelerate decision velocity. The approach enables organizations to anticipate disruption, evaluate trade-offs, and act with confidence in increasingly volatile supply chain environments.From reactive to proactive supply chain planningTraditional planning cycles are often too slow to keep pace with today's volatility. Unison Decision-Centric Planning replaces static, process-driven planning with a dynamic, decision-first approach that continuously senses change, identifies relevant scenarios, and quantifies business impact. By aligning AI-driven intelligence with human judgment, organizations move from reactive firefighting to proactive value optimization."With Unison Decision-Centric Planning, we help customers move beyond reactive firefighting," said Tom Wouters, Chief Product Officer at OMP."By combining human expertise with advanced AI and scenario modeling, we enable confident, proactive decisions that drive agility, resilience, and measurable business impact."Human-AI synergy for smarter, faster decisionsUnison Decision-Centric Planning leverages UnisonIQ to orchestrate AI agents, generative AI assistants, and advanced optimization engines. Routine manual tasks are automated, freeing planners to focus on cross-functional collaboration and decision-making. Explainable AI ensures transparency and trust, while autonomous agents continuously monitor supply chain signals and act in real time.Proven impact at Evonik OxenoEvonik Oxeno, a leading producer of C4 chemicals, partnered with OMP to transition from reactive planning to always-on, scenario-based decision-making. By leveraging real-time insights and simulations through Unison Planning, planners can anticipate disruptions and respond faster, improving agility and overall business performance."Unison Decision-Centric Planning has reinforced trust in the system among planners and executives. Scenario-based decision-making enables us to respond faster and improve company performance," said David Kochanek, Supply Chain Solution Manager at Evonik Oxeno."Scenario-based decision-making enables us to respond faster and improve company performance."Always-on decision intelligence at scaleUnison Decision-Centric Planning introduces event-driven agents that continuously assess opportunities or risks, aligning decisions with strategic and financial objectives. By running hundreds of scenarios, organizations can anticipate disruption, optimize outcomes, and achieve measurable gains in service levels, cost efficiency, sustainability, and decision velocity."Organizations can run hundreds of scenarios to prepare for disruptions and optimize outcomes."Learn more about decision-centric planningDiscover how decision-centric planning can transform your supply chain. Explore OMP's resources, including the always-on e-book and the full Evonik Oxeno success story. Learn more.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics - benefit from using OMP's unique Unison Planning™.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Mar 4, 2026 - (ACN Newswire via SeaPRwire.com) - JCB Co., Ltd. (JCB), together with Resona Holdings, Inc. (Resona; TSE: 8308), announced the start of a project to commercialize ultra-wideband (UWB) payments that realize a new purchasing experience using UWB communication.The two companies have agreed to launch the world's first full-scale project for the practical application and commercialization of UWB payments. In 2026, JCB will work with multiple technology partners and collaborating merchants to demonstrate payment technology and value-added solutions for merchants, as well as user experience building projects to create new purchasing experiences. On top of that, JCB aims to launch small-scale commercial operations in 2027 and full-scale commercialization in earnest in 2028.The two companies are participating in the FiRa® Consortium, which standardizes and contributes to the development of UWB communication technology, as well as builds new payment experiences and value-added solutions for stores using UWB technology.About the UWB Payment ProjectThrough the activities of the FiRa Consortium, JCB, and Resona will standardize technologies and experiences for payment applications, and with the support of FiRa Consortium’s participating vendors, conduct technology tests. From 2026, the two companies will demonstrate UWB payments and value-added solutions together with multiple partner merchants and provide feedback to FiRa on the necessary technology development.In parallel, JCB and Resona will conduct research on user experience and store payment operations to confirm user and merchant acceptability.Moreover, to reduce the introduction load for merchants as much as possible, the project aims to build a payment infrastructure that can widely accept payment solutions using UWB from competitors. The project is aimed to launch on a small scale in 2027 and commercialize on a full-scale in 2028.In addition, the two companies will aim to realize new UWB payments through collaboration with a wide range of partners in Japan and other countries.Image of UWB paymentThe Background of This ProjectUWB communication technology is a short-range wireless communication technology that has the characteristics of (1) accurate location of devices and (2) high-speed data communication and is being used in Japan and overseas for location verification of digital keys for cars and homes, indoor navigation, and tags.The technology is also used overseas in gateless public transportation systems. In the future, it is expected to be used for payments, as with NFC (Near Field Communication) and QR codes.Outside Japan, the spread of smartphones with UWB functions has been slow, but in Japan, smartphones that can use UWB communication are widely available, and can be utilized in advance of the rest of the world. Moreover, the diversification of cashless payments and the wide range of value-added solutions for users and stores are also characteristics of Japan's payment scene. The project believes that it is necessary to take advantage of this location and create new payment solutions to solve problems for users and stores and meet the needs of new solutions.Overview of “UWB Payments”UWB payments can greatly improve the purchasing experience. Until now, it has been necessary to physically touch a card or smartphone at a payment terminal in a merchant or to scan a QR code. UWB payments will leverage short-range communication characteristics to create a new purchasing experience, such as hands-free payments even with a smartphone in a pocket or bag, and to instantly convey user information, such as diet restrictions, to merchants.Also, by utilizing the accurate location information of smartphones, it is possible to realize value-added solutions for both users and merchants that have never been seen before, such as improving the efficiency of navigation and waiting in stores, distributing personalized advertisements and coupons using smart displays, and providing new customer service for VIP customers. It is expected to be used not only to improve the experience but also to be used as a labor-saving solution to address labor shortages.Comparison of NFC and UWB paymentsExamples of value-added solutions:Provide communication functions for both users and merchants. For example, it can be used to automate the communication of requests such as food allergy information, whether or not plastic bags are needed, whether receipts are present and addressed, loyalty program information, whether coupons are available and used, and requests such as handicap and assistance needs, and children's chair preparations.Provide special customer service experiences for VIP customers and support store operations. Customers can receive a special customer service experience without verbally communicating with the merchant’s staff, allowing stores to provide appropriate customer service based on specific customer needs.Enable 1-to-1 marketing capabilities for customers. Marketing utilization, such as displaying personalized information on smart displays near customers, distributing coupons to customers, and displaying personalized pricing.Past UWB Payments InitiativesIn January 2024, JCB and Resona entered into a strategic partnership for the "Hands-free Payment" project, an initiative to build a new payment experience that does not require smartphone operation using device-to-device communication technology. Using UWB communication technology by linking the smartphones held by customers who visit the store with payment terminals and various IoT devices installed in the store, it allows customers to complete the payment process from authentication to payment procedure without taking out a smartphone or activating the screen, and even keeping their smartphone in their bag or pocket. By utilizing this solution, customers can grasp information at the time of their visit to the store and receive customer service and new in-store experiences, such as providing services for VIPs, preferential treatment, and coupon distribution.JCB also announced the development of a UWB-enabled app for iPhones and Apple Watches to support the project, along with a reference model of store checkout equipment and the launch of user testing. Through these efforts, JCB and Resona have been discussing and collaborating with their collaborative partners on technologies and business models.Looking ahead, JCB and Resona will work with multiple technology partners and collaborating merchants to carry out proof-of-concept initiatives for payment and merchant value-added solutions in 2026, with a phased commercial rollout planned for 2027 and full-scale commercialization targeted for 2028.About FiRa ConsortiumThe FiRa Consortium is a member-driven organization dedicated to transforming the way we interact with our environment by enabling precise location awareness for people and devices using the secured fine-ranging and positioning capabilities of Ultra-Wideband (UWB) technology. FiRa does this by driving the development of technical specifications and certifications, advocating for effective regulations, and defining a broad set of UWB use cases. To learn more about UWB and the FiRa Consortium, visit www.firaconsortium.org.About Resona Holdings, Inc.With the Group's purpose of "Making the future positive with finance +," we continue to take on the challenge of transformation and creation in order to transform the future into a positive one with ideas that go beyond the framework of finance. Adhering to our basic stance of "customer joy is Resona's joy," we will work to "strengthen value creativity" and "next-generation management infrastructure" to respond to customers and local communities.About JCB Co., Ltd.JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 71 million merchants worldwide. JCB Cards are now issued mainly in Asian countries and territories, with more than 175 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solutions provider, JCB is committed to delivering responsive, high-quality products and services to all customers worldwide.For more information, please visit: www.global.jcb/en/ContactAnna TakedaJCB Corporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

比利时安特卫普, 2026年3月3日 - (亚太商讯 via SeaPRwire.com) - 人工智能驱动的供应链规划解决方案领先供应商OMP推出Unison决策导向型规划，该创新方法助力企业实现从被动流程驱动规划向主动事件驱动决策的转型。该方案基于OMP旗舰产品Unison Planning™平台构建，融合先进人工智能、自主智能体、实时场景建模与人工验证，显著提升决策速度。在日益动荡的供应链环境中，该方案助力企业预判中断风险、评估权衡取舍并果断采取行动。从被动转向主动的供应链规划传统规划周期往往难以应对当今的剧烈波动。Unison决策导向型规划以动态决策优先模式取代静态流程驱动规划，持续感知变化、识别相关场景并量化业务影响。通过融合人工智能洞察与人类判断，企业得以从被动救火转向主动价值优化。“借助Unison决策导向型规划，我们助力客户摆脱被动救火模式，”OMP首席产品官Tom Wouters表示。“通过融合人类专业知识与先进AI及场景建模技术，我们赋能企业做出自信主动的决策，从而提升敏捷性、韧性并创造可量化的商业价值。”人机协同，决策更智能高效Unison决策导向型规划依托UnisonIQ平台，协同调度AI智能体、生成式AI助手及高级优化引擎。常规手动任务实现自动化，使规划人员能专注于跨职能协作与决策制定。可解释AI确保透明度与信任度，自主智能体持续监测供应链信号并实时响应。赢创奥克赛诺的实践成效作为C4化工领域领军企业，赢创奥克赛诺携手OMP实现规划模式转型——从被动响应转向持续在线的场景化决策。通过Unison Planning获取实时洞察与模拟分析，规划人员能预判中断风险并加速响应，显著提升敏捷性与整体业务绩效。“Unison决策导向型规划增强了规划人员与管理层对系统的信任。基于情景的决策使我们能够更快响应并提升公司绩效，”赢创奥克西诺供应链解决方案经理David Kochanek表示。“基于情景的决策使我们能够更快响应并提升公司绩效。”大规模持续决策智能Unison决策导向型规划引入事件驱动型智能代理，持续评估机遇与风险，使决策与战略及财务目标保持一致。通过运行数百种场景，企业可预判中断风险、优化结果，并在服务水平、成本效率、可持续发展及决策速度方面实现可量化的提升。“企业可运行数百种场景以应对中断风险并优化结果。”深入了解决策导向型规划探索决策导向型规划如何重塑您的供应链。查阅OMP资源库，包括持续更新的电子书及赢创Oxeno完整成功案例。了解更多。关于OMPOMP为面临复杂规划挑战的企业提供业界顶尖的数字化供应链规划解决方案，助力企业卓越发展、持续成长。数百家跨行业客户——涵盖消费品、生命科学、化工、金属、造纸、包装、塑料等领域——正受益于OMP独特的Unison Planning™解决方案。解决方案与产品咨询联系OMP媒体咨询Kira Perdue (Carabiner)来源：OMP Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月3日 - (亚太商讯 via SeaPRwire.com) - 五矿资源有限公司（「MMG」；股份代号：1208）今日发布二零二五年年度业绩，营业收入与利润均创历史新高。这一优异成绩，体现了公司卓越的运营与财务管理，同时受益于有利的商品价格。观看五矿资源行政总裁赵晶先生致辞视频：https://drive.google.com/file/d/1iini4Eu_ACtpHlC9E6i6B5P2k6qntUJu/view?usp=sharing安全始终是五矿资源的首要价值。2025年全年，公司可记录总工伤事故频率（TRIF）为每百万工时2.06。具有能量交换的重大事件频率（SEEEF）为每百万工时0.80，较2024年的0.78略有上升。公司总体盈利水平创历史新高。EBITDA 达到 34.12 亿美元，EBIT 增至 19.99 亿美元。五矿资源同时实现创纪录的经营活动现金流净额 26.90 亿美元、自由现金流 16.08亿美元。税后净利润增至 9.55 亿美元（包括权益持有人应占利润 5.09 亿美元），较 2024 年的 3.66 亿美元（包括权益持有人应占利润 1.62 亿美元）大幅增长。五矿资源行政总裁赵晶先生表示：「公司全年业绩强劲收官，运营和财务表现都十分出色。其中Las Bambas矿山实现了有史以来第二高的年度铜产量，较2024年增长27%，并在年采矿量、选矿量及总回收率上均创下纪录。」五矿资源的资产负债表大幅增强，净负债进一步下降，杠杆率降至33%的历史低位。这部分得益于Las Bambas合营公司的股息分配，帮助公司提前偿还了Khoemacau 项目 5 亿美元贷款。剩余资金用于偿还其他债务、降低公司杠杆水平，并支持 Khoemacau 扩建项目的前期工作。得益于技术、创新以及Las Bambas两个采场的稳定运营，五矿资源 铜总产量同比增长 27%，达到 506,899 吨。2025 年Las Bambas实现收入 44.47 亿美元（同比增长 49%），是公司收入增长的最大贡献来源。锌总产量增长 6%，达到 232,060 吨，主要得益于Dugald River矿山的创纪录表现。Rosebery矿山的贵金属产量同样表现良好。赵先生表示：「我们会持续关注变化的市场环境，同时专注推进增长计划，并通过运用新兴技术为股东创造长期价值。Khoemacau 扩建项目是 五矿资源 增长战略的重要一环。我们计划在 2028 年将铜精矿含铜的年产能提升至 13 万吨，并在未来有望达到 20 万吨。」2025 年，公司市值超过 1,000 亿港元，首期可转换债券也获得强劲认购。五矿资源 2025 年年度业绩报告可点击此处查阅。Las BambasKhoemacauDugald RiverRosebery Kinsevere按此下载新闻稿图片： https://drive.google.com/drive/folders/1o9ArIgbJSAT2z1UCt8ttB69L9l9jiebx?usp=drive_link关于MMG五矿资源成立于二零零九年，其愿景是为低碳未来打造国际领先的矿业公司。公司总部位于澳大利亚墨尔本和中国北京，并在香港联合交易所上市（联交所：1208）。五矿资源的资产组合涵盖铜、锌和钴的生产，并即将拓展至镍领域。这些金属资源对全球脱碳和电气化目标的实现至关重要。目前，公司的运营业务遍布澳大利亚、博茨瓦纳、刚果民主共和国及拉丁美洲，为所在国家的经济与社会发展作出直接贡献。2025 年，五矿资源发布了首份自然战略，并推进气候战略的更新工作。五矿资源加入联合国全球契约组织（UN Global Compact），进一步使公司在人权、气候行动及公司治理等方面与全球领先水平保持一致。更多信息请点击此处。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月3日 - (亚太商讯 via SeaPRwire.com) - 3月2日，MiniMax（股票代码：00100.HK）发布2025年全年业绩公告，同时披露2026年开年以来的强劲增长表现，2026年2月公司年度经常性收入（ARR）突破1.5亿美元，迎来业务发展的重要跃升。财报数据显示，MiniMax2025年总营收达7903.8万美元，同比增长158.9%，业务板块均实现高速增长。其中AI原生产品收入5307.5万美元，同比增143.4%；开放平台及企业服务收入2596.3万美元，同比增幅达197.8%。全球化布局成效显著，该年度公司国际市场收入占比73%，已服务全球200余个国家和地区的2.36亿用户，以及21.4万企业客户与开发者。2026年开年，MiniMax增长态势进一步提速，2月开放平台新注册用户数较2025年12月超4倍增长，M2系列文本模型平均单日Token消耗量增幅超6倍，其中Coding Plan相关Token消耗增长更是突破10倍。在此背景下，公司正式宣布从大模型企业向AI时代平台型企业迈进，并将AI平台价值定义为“智能密度 × Token 吞吐量”，锚定两大核心指标构建平台化能力。针对2026年AI行业趋势，MiniMax作出三大判断，认为编程领域将迎来L4-L5级智能，实现从工具到同事级的协作升级；办公领域AI智能体的交付与渗透速度将大幅提升；多模态创作则将实现可交付中长内容的直出，甚至走向实时输出形态，而三大趋势叠加或将推动Token量级实现1-2个数量级的增长。目前公司已启动M3及Hailuo 3系列模型研发，同时内部AI原生组织实践落地，超90%员工日常工作场景覆盖内部Agent，为模型迭代提供直接反馈。业绩增长的同时，MiniMax的盈利与研发效率也同步提升。2025年公司毛利额约2007.9万美元，同比大增437.2%，毛利率从2024年的12.2%提升至25.4%，核心得益于推理成本的持续下降，2026年2月M2系列文本模型每百万Token推理算力成本较2025年12月下降超50%。费用结构也持续优化，研发费用同比增33.8%的同时，营销费用同比下降40.3%。此外，MiniMax的全模态技术能力持续夯实，2025年108天内完成M2系列三版模型迭代，视频、语音模型分别累计生成超6亿个视频、2亿小时语音，为跨模态融合奠定基础。凭借成熟的商业化路径、持续优化的成本结构与全球化商业生态，MiniMax已初步夯实AI平台型公司的战略定位，为迎接新一轮行业智能红利做好充分准备。公司创始人、CEO闫俊杰表示，MiniMax将始终以技术创新为核心，持续提升智能密度与Token吞吐效率，以平台化能力携手全球客户与开发者，共同挖掘AI时代的全新商业价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – On 02 March 2026, Concord New Energy Group (“CNE Group”) signed a Memorandum of Understanding (MOU) in Singapore with Bridge Data Centres (BDC), a portfolio company of Bain Capital.Under the MOU, the parties will jointly explore diversified energy supply pathways integrating renewable energy and hydrogen solutions on a global basis to support the low-carbon transformation of data centre infrastructure. The collaboration includes the development of Singapore’s first barge-based hydrogen power generation solution designed specifically for artificial intelligence (AI) digital infrastructure.The partnership will encompass hydrogen power pathway studies, system integration design, energy storage deployment assessments, and optimization of power procurement mechanisms. Through these initiatives, both parties aim to enhance energy reliability, operational flexibility, and long-term sustainability for next-generation data centre campuses.CNE brings extensive expertise in renewable energy development and integrated energy systems, while BDC contributes leading operational capabilities in digital infrastructure. The collaboration is expected to accelerate the convergence of clean energy solutions and advanced computing infrastructure.As artificial intelligence and high-performance computing continue to reshape regional economies, this partnership will further support Singapore’s ambition to remain a leading digital hub powered by low-carbon energy.Bridge Data Centres (BDC)Headquartered in Singapore, Bridge Data Centres (BDC) is a leading hyperscale data centre platform in the Asia Pacific region backed by Bain Capital. The company focuses on the development and operation of high-performance digital infrastructure across multiple high-growth markets. BDC is committed to delivering resilient, reliable, and sustainable infrastructure solutions to support the rapid growth of cloud computing and artificial intelligence (AI) applications.Concord New Energy Group (CNE)Headquartered in Singapore, Concord New Energy Group is a renewable energy developer and operator listed on the Main Board of the Hong Kong Stock Exchange and the Singapore Exchange. With 20 years of experience in the renewable energy industry, CNE’s portfolio covers wind power, photovoltaic (PV) and energy storage projects. The Group has strong capabilities in project development, investment, construction and long-term asset management, and currently holds over 5GW of equity capacity globally. CNE remains committed to promoting the application of clean energy and providing integrated energy solutions to support sustainable development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 中国内地以外首款获批的葡萄糖激酶激活剂（GKA）- 本次获批为2型糖尿病的差异化治疗提供新方案- 中国香港将成为华领医药国际化市场拓展的重要起点上海，香港, 2026年3月3日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552）今日宣布，其全球首创新药葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin）（商品名：MYHOMSIS(R)，華領片(R)）已获中国香港特别行政区政府卫生署药物办公室批准上市，用于治疗成人2型糖尿病。依托香港优化的"1+"药物监管创新机制，2025年9月，香港卫生署正式受理多格列艾汀的新药上市申请（NDA），作为"1+"机制开展以来，首个获批上市的慢性代谢病创新药，多格列艾汀的成功落地不仅为香港地区2型糖尿病患者带来全新治疗选择，更标志着华领医药以香港为枢纽，从中国正式进军东南亚及全球市场的战略布局已迈出关键一步。华领医药集团运营和大湾区发展部副总裁曹蓓莉介绍："本次在'1+'机制下获批的三个新药中，華領片(R)是获得中国国家药品监督管理局批准的中国创新药，也是'1+'机制下获批的首个普药。"华领医药创始人、执行董事兼CEO陈力博士表示："多格列艾汀在香港的获批上市，是公司发展历程中的重要里程碑。作为香港'1+'机制下获益的首批原研创新药，这一成果不仅体现了香港对创新药的支持，更验证了中国自主研发创新药的全球竞争力。香港上市是华领医药进军东南亚及国际市场的关键一步，我们将以香港为枢纽，构建辐射东南亚、连接全球的营销网络与研发合作体系，让中国自主研发的创新药惠及更多国家和地区的糖尿病患者。同时，我们将持续推进多格列艾汀在中国澳门特别行政区的上市进程，实现其在粤港澳大湾区的全面落地，并依托此区域政策人才和医疗资源优势，推进新适应症的临床拓展和華領片(R)的国际推广。"全球首创+成熟临床数据，建立重塑血糖稳态治疗新范式2型糖尿病是一种进展性疾病，其核心特征是人体血糖调节功能受损，胰岛β细胞功能也会随着病程进展逐步衰退。当前多数治疗方案仅针对血糖紊乱引发的下游症状进行干预，多格列艾汀是华领医药自主研发的全球首创GKA类新药，其核心创新在于通过修复2型糖尿病患者受损的葡萄糖激酶（GK）功能和表达，从源头上提升患者的葡萄糖敏感性，改善血糖稳态失调。该药物可作用于胰岛、肠道、肝脏等多个葡萄糖代谢关键器官，通过多靶点协同作用：- 促进胰岛β细胞在血糖刺激下分泌胰岛素；- 促进肠道L细胞分泌胰高血糖素样肽-1（GLP-1）；- 通过调节肝糖原代谢，调控肝脏的葡萄糖输出这种多器官协同的作用特征，让多格列艾汀区别于现有口服降糖药物，也体现出华领医药从源头改善血糖稳态失衡问题，控制2型糖尿病的进展及其并发症发生的研发核心思路。多格列艾汀于2022年9月获得中国国家药品监督管理局（NMPA）的上市批准，获批两个适应症：1）单独用药治疗未经药物治疗的2型糖尿病患者，可以用于一线治疗；2）在单独使用盐酸二甲双胍血糖控制不佳时，与盐酸二甲双胍联合使用，改善成人2型糖尿病患者的血糖控制。自2024年1月1日起，多格列艾汀已被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》，截至目前，中国大陆已有超 20 万名患者使用该药物。去年6月，在美国糖尿病协会（ADA）科学年会上发表的真实世界研究中期分析，进一步验证了其在广泛人群中的有效性与安全性。借力香港"1+"政策，创新药加速惠及港民香港"1+"药物监管创新机制的制定与实施，是香港特区政府为提升医疗创新可及性、吸引全球优质创新药落地推出的重要举措。该政策允许已在指定主要市场（如中国内地、美国、欧洲等）获批的创新药，通过简化的申报路径和数据互认机制，快速在香港完成上市审批，大幅缩短创新药从研发到惠及香港患者的时间周期，同时保障药品的安全性与有效性。多格列艾汀凭借其在中国内地的成熟临床数据、明确的治疗价值及良好的安全性记录，成为通过香港"1+"机制快速获批的首批中国原创新药。此次获批是该政策赋能全球创新药落地香港的重要实践成果，不仅体现了香港卫生署对多格列艾汀临床价值的高度认可，更彰显了"1+"机制在连接内地与国际医药市场、加速创新医疗资源流动方面的核心作用。立足香港经验，赋能全球糖尿病管理糖尿病是全球公共卫生领域的重大难题。国际糖尿病联盟（IDF）2025年发布的全球糖尿病地图显示，2024年，全球20-79岁的成年人中，糖尿病患者人数高达5.89亿，预计到2050年，这一数字将攀升至8.53亿。在中国香港地区，糖尿病也是一个突出的公共卫生问题。根据香港卫生署2020-2022年度人口健康调查，15岁或以上人士中，6.9%的人表示经医生诊断患上糖尿病，另有1.8%有高血糖但并未患上糖尿病。2022年，香港因糖尿病导致的死亡登记人数超过600人，在主要死因中排名第十一位。[1]香港在糖尿病管理方面拥有丰富经验，形成了涵盖疾病监测、预防、筛查、治疗及社区管理的完善体系，其社区为本的公私营协作糖尿管理模式成效显著。多格列艾汀在香港上市后，预计将与当地成熟的糖尿病管理体系深度融合，通过个性化治疗方案助力提升患者生活质量、控制病情进展及减轻医疗负担。目前，华领医药正在与国际著名内分泌专家、香港中文大学Juliana Chan教授团队合作，开展SENSITIZE系列研究，以不断探索多格列艾汀改善β细胞葡萄糖敏感性的作用机制。已经公布的SENSITIZE1/2研究显示，多格列艾汀可以显著改善葡萄糖激酶单基因遗传突变糖尿病 (GCK-MODY或MODY-2)患者的胰岛素第二时相分泌和β细胞葡萄糖敏感性，可以显著改善初发2型糖尿病患者的基础胰岛素分泌；多格列艾汀还可以显著改善葡萄糖耐量异常（IGT）人群的二相胰岛素分泌和β细胞葡萄糖敏感性。华领医药将继续与本地顶尖科研机构和临床医生深度合作，进一步挖掘多格列艾汀在糖尿病前期干预、早期治疗和并发症预防方面的潜力，积累更多国际化临床数据，为其在全球范围内的适应症拓展和市场推广积累关键数据，并且建立糖尿病前期和2型糖尿病患者的个性化干预和治疗管理方案。作为亚洲医药市场的核心枢纽，香港凭借其独特的地理位置、完善的医疗基础设施、国际化的营商环境及与东南亚市场的紧密联动优势，有望成为华领医药进军东南亚乃至全球市场的战略起点。依托香港的药品监管标准与国际接轨的优势，利用香港的金融与资本市场优势，华领医药将进一步推动多格列艾汀在东南亚市场的注册申报，快速覆盖该地区庞大的糖尿病患者群体。同时，深化与全球医药产业链伙伴的合作，加速推进多格列艾汀的国际化商业化进程。前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁(R)已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）获得中国香港特别行政区政府卫生署药物办公室的上市批准。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com[1] 2020-22年度人口健康调查报告书，中国香港卫生署卫生防护中心，https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- First glucokinase-activator (GKA) approval outside mainland China- Approval supports a differentiated approach to Type 2 diabetes (T2D) management- Hong Kong will serve as Hua Medicine’s launchpad for international market expansionSHANGHAI, HONG KONG, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.Under Hong Kong's "1+" pharmaceutical regulatory innovation mechanism, the approval follows the acceptance of dorzagliatin’s New Drug Application (NDA) by the Hong Kong Department of Health in September 2025. As the first innovative drug for chronic metabolic diseases approved for marketing since the launch of "1+" mechanism, the successful rollout of dorzagliatin not only brings an entirely new treatment option for patients with Type 2 diabetes in Hong Kong, but also marks a crucial step in Hua Medicine's strategic layout to expand from China to the Southeast Asian and global markets with Hong Kong as its hub.Cao Beili, Vice President of Department of Corporate Operation and Great Bay Development of Hua Medicine, stated: “Among the three new drugs approved under the ‘1+’ mechanism, MYHOMSIS(R) is an innovative medicine developed in China that has obtained approval from the National Medical Products Administration (NMPA). It is also the first primary care drug product approved under the ‘1+’ mechanism.”Dr. Chen Li, Founder, Executive Director and CEO of Hua Medicine, stated: "The approval of dorzagliatin for marketing in Hong Kong is a significant milestone in the Company's development. As one of the first original innovative drugs to benefit from Hong Kong's '1+' mechanism, this achievement not only reflects Hong Kong's support for innovative drugs, but also validates the global competitiveness of China's independently developed innovative drugs. The launch in Hong Kong is a key step for Hua Medicine to enter the Southeast Asian and international markets. We will take Hong Kong as the hub to build a marketing network and R&D cooperation system radiating Southeast Asia and connecting the world, bringing China's independently developed innovative drugs to more diabetes patients in countries and regions around the globe. Meanwhile, we will continue to advance the marketing approval process of dorzagliatin in the Macao Special Administrative Region of China to achieve its full rollout in the Guangdong-Hong Kong-Macao Greater Bay Area, and relying on the regional advantages in mechanisms, talent and medical resources, we will advance the clinical expansion of new indications and the international promotion of MYHOMSIS(R)."Global First-in-Class & Local Clinical Data: Establishing a New Model for Restoring Glycemic Homeostasis in Diabetes TreatmentType 2 diabetes remains a progressive disease characterized by impaired glucose regulation and declining pancreatic β-cell function over time. While many therapies address downstream consequences of dysregulated blood glucose, dorzagliatin is a global first-in-class GKA innovative drug independently developed by Hua Medicine. Its core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, thereby improving patients' glucose sensitivity from the source and ameliorating the imbalance of glycemic homeostasis. The drug acts on multiple key organs of glucose metabolism including the islets, intestines and liver, exerting a synergistic effect through multiple targets:- enhancing glucose-stimulated insulin secretion from pancreatic β-cells, - promoting GLP-1 release from intestinal L-cells, and - modulating hepatic glucose output through glycogen regulation.This coordinated, multi-organ profile differentiates dorzagliatin from existing oral antidiabetic therapies and reflects Hua Medicine’s focus on addressing glucose homeostasis dysregulation and controlling the progression of Type 2 diabetes and the occurrence of its complications from the source.Dorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients:1) It can be used as mono-therapy treatment for drug-naïve T2D patients, as first-line treatment,2) When metformin hydrochloride alone exhibits poor blood glucose control in T2D patients, it can be used in combination with metformin hydrochloride.Since January 1, 2024, dorzagliatin is included in China’s National Reimbursement Drug List and has been prescribed to over 200,000+ patients in mainland China already. In June last year, the interim analysis of real-world research presented at the Scientific Sessions of the American Diabetes Association (ADA) further verified its efficacy and safety in a broad population.Leveraging Hong Kong's "1+" Mechanism to Accelerate Access to Innovative Drugs for Hong Kong ResidentsThe formulation and implementation of Hong Kong's "1+" pharmaceutical regulatory innovation mechanism is an important measure taken by the Hong Kong SAR Government to enhance the accessibility of medical innovation and attract high-quality global innovative drugs to launch in Hong Kong. This mechanism allows innovative drugs already approved in designated major markets (such as China, the United States, Europe, etc.) to secure marketing approval in Hong Kong through a simplified application pathway and data mutual recognition mechanism, which greatly shortens the time cycle from R&D to clinical access of innovative drugs for Hong Kong patients, while ensuring the safety and efficacy of the drugs.With its local clinical data, clear therapeutic value and good safety record in China, dorzagliatin has become one of the first original Chinese innovative drugs to be rapidly approved through Hong Kong's "1+" mechanism. This approval is an important practical achievement of the mechanism in enabling the launch of global innovative drugs in Hong Kong, which not only reflects the high recognition of the clinical value of dorzagliatin by the Department of Health of Hong Kong, but also highlights the core role of the "1+" mechanism in connecting the Chinese market and international pharmaceutical markets and accelerating the flow of innovative medical resources.Building on Hong Kong's Experience to Empower Global Diabetes ManagementDiabetes is a major challenge for global public health. According to the 2025 Global Diabetes Map released by the International Diabetes Federation (IDF), the number of adults aged 20-79 with diabetes worldwide reached 589 million in 2024, and this figure is projected to rise to 853 million by 2050. In Hong Kong, China, diabetes is also a prominent public health issue. According to the Population Health Survey 2020-2022 conducted by the Department of Health of Hong Kong, 6.9% of people aged 15 or above reported having been diagnosed with diabetes by a doctor, and an additional 1.8% had hyperglycemia without being diagnosed with diabetes. In 2022, more than 600 death registrations in Hong Kong were attributed to diabetes, ranking 11th among the leading causes of death.[1]Hong Kong has accumulated rich experience in diabetes management, forming a comprehensive system covering disease surveillance, prevention, screening, treatment and community management, and its community-based public-private partnership model for diabetes management has achieved remarkable results. Following its launch in Hong Kong, dorzagliatin is expected to be deeply integrated with the local mature diabetes management system, and help improve patients' quality of life, control disease progression and reduce medical burdens through personalized treatment plans.At present, Hua Medicine is collaborating with the research team led by Professor Juliana Chan, a world-renowned endocrinologist from the Chinese University of Hong Kong, to conduct the SENSITIZE series of studies to further explore the mechanism by which dorzagliatin improves pancreatic β-cell glucose sensitivity. The published results of the SENSITIZE 1/2 studies have shown that dorzagliatin can significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and enhance basal insulin secretion in patients with newly diagnosed type 2 diabetes. In addition, dorzagliatin can also significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in populations with impaired glucose tolerance (IGT).Hua Medicine will continue to deepen cooperation with top local research institutions and clinicians to further explore the potential of dorzagliatin in pre-diabetes intervention, early treatment and complication prevention, accumulate additional international clinical data, lay a solid foundation for the expansion of its indications and global market promotion, and establish personalized intervention and treatment management plans for patients with pre-diabetes and Type 2 diabetes.As a core hub of the Asian pharmaceutical market, Hong Kong, with its unique geographical location, advanced medical infrastructure, international business environment and close linkage with the Southeast Asian market, is expected to become the strategic starting point for Hua Medicine to expand into Southeast Asia and the global market. Relying on Hong Kong's advantage of pharmaceutical regulatory standards aligned with international norms and leveraging its financial and capital market strengths, Hua Medicine will further advance the registration and application of dorzagliatin in the Southeast Asian market to quickly cover the large population of diabetes patients in the region. Meanwhile, the Company will deepen cooperation with partners in the global pharmaceutical industry chain to accelerate the international commercialization of dorzagliatin.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS(R)) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail:pr@huamedicine.com[1] https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月3日 - (亚太商讯 via SeaPRwire.com) - 上周五，中证指数有限公司正式发布中证港股通机器人主题指数（代码：932599），该指数旨在追踪港股通范围内机器人主题上市公司的整体表现。作为中国骨科医疗领域的领先企业，爱康医疗（1789.HK）成功获纳入该指数成份股，标志着公司在医疗机器人领域的创新实力及商业化能力获得市场认可，有望提升爱康医疗的投资者关注度。中证港股通机器人主题指数（932599.CSI）由中证指数有限公司编制，成份股数量为30只，覆盖港股通范围内为机器人智能化提供关键技术的企业。这些公司涉及感知、规划决策、运动控制与执行等核心环节的软件和硬件产品，包括传感器、人工智能算法、自动化设备等细分领域。该指数的推出，为投资者提供了便捷的工具，以把握机器人产业在工业、医疗、服务等应用场景中的增长机遇。爱康医疗是中国骨科植入物领域的创新领导者，自2003年成立以来，始终致力于通过前沿技术推动骨科医疗发展。比如，其自主研发的关节置换手术导航定位系统（K3+智能手术机器人）就融合了高精度感知，符合该指数对“机器人智能化”主题的严格筛选标准。爱康医疗的纳入反映了其在港股通板块中的代表性，以及医疗机器人行业在人口老龄化和技术升级趋势下的高潜力。指数纳入通常意味着成份股将获得被动资金跟踪，例如挂钩该指数的ETF或衍生品。中证港股通机器人主题指数作为新兴投资标的，有望吸引境内外机构资金配置。爱康医疗此次入选，或有助于扩大投资者基础，优化股权结构，并进一步巩固其在全球医疗科技竞争中的地位。随着人工智能与机器人技术的深度融合，中证港股通机器人主题指数有望成为港股市场的重要风向标。爱康医疗的加入，不仅是对其技术实力的肯定，也为整个医疗机器人赛道带来积极信号。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com